Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Medicure Inc. stock logo
MPH
Medicure
C$1.02
-6.4%
C$1.14
C$0.99
C$1.80
C$10.46M1.014,477 shs10,000 shs
Matinas BioPharma Holdings, Inc. stock logo
MTNB
Matinas BioPharma
$0.18
$0.00
$0.11
$0.89
$39.47M1.521.39 million shs681,612 shs
Resverlogix Corp. stock logo
RVX
Resverlogix
C$0.06
C$0.06
C$0.05
C$0.15
C$14.97M0.7836,842 shs7,200 shs
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Medicure Inc. stock logo
MPH
Medicure
-6.42%-0.97%-15.00%-12.07%-22.14%
Matinas BioPharma Holdings, Inc. stock logo
MTNB
Matinas BioPharma
0.00%0.00%0.00%-19.39%-38.26%
Resverlogix Corp. stock logo
RVX
Resverlogix
-8.33%0.00%0.00%-21.43%-59.26%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Medicure Inc. stock logo
MPH
Medicure
N/AN/AN/AN/AN/AN/AN/AN/A
Matinas BioPharma Holdings, Inc. stock logo
MTNB
Matinas BioPharma
0.9932 of 5 stars
3.54.00.00.00.00.00.0
Resverlogix Corp. stock logo
RVX
Resverlogix
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Medicure Inc. stock logo
MPH
Medicure
N/AN/AN/AN/A
Matinas BioPharma Holdings, Inc. stock logo
MTNB
Matinas BioPharma
3.00
Buy$3.001,552.89% Upside
Resverlogix Corp. stock logo
RVX
Resverlogix
N/AN/AN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Medicure Inc. stock logo
MPH
Medicure
C$22.94M0.46C$0.41 per share2.49C$2.10 per share0.49
Matinas BioPharma Holdings, Inc. stock logo
MTNB
Matinas BioPharma
$1.10M35.88N/AN/A$0.09 per share2.02
Resverlogix Corp. stock logo
RVX
Resverlogix
N/AN/AC$0.00 per share132.50C($0.26) per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Medicure Inc. stock logo
MPH
Medicure
C$1.08MC$0.0911.33N/A4.71%5.04%2.49%5/24/2024 (Estimated)
Matinas BioPharma Holdings, Inc. stock logo
MTNB
Matinas BioPharma
-$22.94M-$0.12N/AN/AN/A-89.20%-72.15%5/8/2024 (Estimated)
Resverlogix Corp. stock logo
RVX
Resverlogix
-C$12.82M-C$0.05N/AN/AN/AN/A-37.10%5/9/2024 (Estimated)

Latest MPH, RVX, and MTNB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/8/2024Q4 2023
Medicure Inc. stock logo
MPH
Medicure
N/A-C$0.14-C$0.14-C$0.14N/AC$5.07 million
4/1/2024Q4 2023
Resverlogix Corp. stock logo
RVX
Resverlogix
N/A-C$0.01-C$0.01-C$0.01N/AN/A
3/27/2024Q4 2023
Matinas BioPharma Holdings, Inc. stock logo
MTNB
Matinas BioPharma
N/A-$0.03-$0.03-$0.03N/AN/A    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Medicure Inc. stock logo
MPH
Medicure
N/AN/AN/AN/AN/A
Matinas BioPharma Holdings, Inc. stock logo
MTNB
Matinas BioPharma
N/AN/AN/AN/AN/A
Resverlogix Corp. stock logo
RVX
Resverlogix
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Medicure Inc. stock logo
MPH
Medicure
2.86
2.28
1.29
Matinas BioPharma Holdings, Inc. stock logo
MTNB
Matinas BioPharma
N/A
5.93
5.93
Resverlogix Corp. stock logo
RVX
Resverlogix
N/A
0.11
0.04

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Medicure Inc. stock logo
MPH
Medicure
23.10%
Matinas BioPharma Holdings, Inc. stock logo
MTNB
Matinas BioPharma
11.77%
Resverlogix Corp. stock logo
RVX
Resverlogix
N/A

Insider Ownership

CompanyInsider Ownership
Medicure Inc. stock logo
MPH
Medicure
26.99%
Matinas BioPharma Holdings, Inc. stock logo
MTNB
Matinas BioPharma
9.60%
Resverlogix Corp. stock logo
RVX
Resverlogix
43.19%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Medicure Inc. stock logo
MPH
Medicure
N/A10.25 millionN/ANot Optionable
Matinas BioPharma Holdings, Inc. stock logo
MTNB
Matinas BioPharma
34217.48 million196.61 millionNot Optionable
Resverlogix Corp. stock logo
RVX
Resverlogix
19272.17 millionN/ANot Optionable

MPH, RVX, and MTNB Headlines

SourceHeadline
Resverlogix Announces Change to Its Board of DirectorsResverlogix Announces Change to Its Board of Directors
finance.yahoo.com - February 21 at 8:02 PM
Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalones Potential Therapeutic BenefitsResverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits
finance.yahoo.com - January 11 at 10:03 AM
Closing Bell: Resverlogix Corp flat on Tuesday (RVX)Closing Bell: Resverlogix Corp flat on Tuesday (RVX)
theglobeandmail.com - January 4 at 6:16 PM
Resverlogix Corp. (RVX) Earnings Dates & ReportsResverlogix Corp. (RVX) Earnings Dates & Reports
investing.com - December 19 at 7:28 PM
Resverlogix Corp RVXCFResverlogix Corp RVXCF
morningstar.com - November 18 at 5:49 PM
Resverlogix Corp RVXResverlogix Corp RVX
morningstar.com - November 1 at 11:18 AM
Resverlogix: Top 10 Undervalued Healthcare Sector Stocks on TSX (RVX)Resverlogix: Top 10 Undervalued Healthcare Sector Stocks on TSX (RVX)
theglobeandmail.com - October 18 at 7:46 AM
Resverlogix Corp.: Resverlogix Publishes on Apabetalones Potential for the Treatment of FSHD, the Third Most Common Muscular DystrophyResverlogix Corp.: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
finanznachrichten.de - October 4 at 10:11 AM
Resverlogix Publishes on Apabetalones Potential for the Treatment of FSHD, the Third Most Common Muscular DystrophyResverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
finance.yahoo.com - October 4 at 10:11 AM
Atherosclerotic Cardiovascular Disease Market to Observe Impressive Growth at a CAGR of 2.2% by 2032, Predicts DelveInsightAtherosclerotic Cardiovascular Disease Market to Observe Impressive Growth at a CAGR of 2.2% by 2032, Predicts DelveInsight
finance.yahoo.com - September 26 at 8:50 PM
Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 DiabetesResverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
finance.yahoo.com - August 29 at 10:13 AM
Closing Bell: Resverlogix Corp up on Wednesday (RVX)Closing Bell: Resverlogix Corp up on Wednesday (RVX)
theglobeandmail.com - August 24 at 3:35 PM
Closing Bell: Resverlogix Corp flat on Monday (RVX)Closing Bell: Resverlogix Corp flat on Monday (RVX)
theglobeandmail.com - August 14 at 10:02 PM
Closing Bell: Resverlogix Corp Warrants down on Wednesday (RVX-WT-A)Closing Bell: Resverlogix Corp Warrants down on Wednesday (RVX-WT-A)
theglobeandmail.com - July 12 at 7:21 AM
Resverlogix Announces Warrant Repricing and One-Year ExtensionResverlogix Announces Warrant Repricing and One-Year Extension
finance.yahoo.com - June 29 at 11:09 PM
Resverlogix Corp.: Resverlogix Announces Voting Results from the 2023 Meeting of ShareholdersResverlogix Corp.: Resverlogix Announces Voting Results from the 2023 Meeting of Shareholders
finanznachrichten.de - June 20 at 7:31 PM
Resverlogix Announces Voting Results from the 2023 Meeting of ShareholdersResverlogix Announces Voting Results from the 2023 Meeting of Shareholders
finance.yahoo.com - June 20 at 7:31 PM
Resverlogix Announces New Insights into the Mechanism of Apabetalones Cardioprotective Benefit in Chronic Kidney Disease PatientsResverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patients
finance.yahoo.com - June 12 at 6:42 PM
Canadian Investment Regulatory Organization Trading Halt - RVX.WT.ACanadian Investment Regulatory Organization Trading Halt - RVX.WT.A
finance.yahoo.com - June 7 at 1:32 PM
Closing Bell: Resverlogix Corp Warrants down on Friday (RVX-WT-A)Closing Bell: Resverlogix Corp Warrants down on Friday (RVX-WT-A)
theglobeandmail.com - June 6 at 10:49 AM
Closing Bell: Resverlogix Corp Warrants down on Tuesday (RVX-WT-A)Closing Bell: Resverlogix Corp Warrants down on Tuesday (RVX-WT-A)
theglobeandmail.com - May 25 at 12:52 AM
CBOE RUSSELL 2000 VOLATILITY IN (^RVX)CBOE RUSSELL 2000 VOLATILITY IN (^RVX)
finance.yahoo.com - May 18 at 12:38 AM
Bromodomain Containing Protein 2 Market is Likely to Upsurge at ... - StreetBuzzBromodomain Containing Protein 2 Market is Likely to Upsurge at ... - StreetBuzz
news.google.com - May 13 at 3:47 PM
Resverlogix : MD&A Q1 2023 - Marketscreener.comResverlogix : MD&A Q1 2023 - Marketscreener.com
news.google.com - May 12 at 3:50 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Medicure logo

Medicure

CVE:MPH
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.
Matinas BioPharma logo

Matinas BioPharma

NYSEAMERICAN:MTNB
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.
Resverlogix logo

Resverlogix

TSE:RVX
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.